Quantitative measurements of expression of various target antigens, including ADGRE2, CD38, CD123, and CLL1, showed that the combinational targeting of ADGRE2 and CLL1 allowed the efficient elimination of AML cells and of patient-derived xenograft models with limited toxicity for normal stem/progenitor cells [98]. The gene discussed is ADGRE2; the disease is acute myeloid leukemia.